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Abstract
Purpose PET/CT, PET+CT, and CT were compared
concerning accuracies in TNM staging and malignancy
detection in head and neck cancer. The impact of PET/CT
compared to the other imaging modalities on therapy
management was assessed.
Materials and methods Fifty-five patients with suspected
head and neck primary cancer underwent whole-body
FDG-PET/CT. PET/CT and PET+CT were evaluated by a
nuclear medicine physician and a radiologist; CT was
evaluated by two radiologists, PET by two nuclear
physicians. Histopathology served as the standard of
reference. Differences between the staging modalities were
tested for statistical significance by McNemar’s test.
Results Overall TNM-staging and T-staging with PET/CT
were more accurate than PET+CT and CT alone (p<0.05).
PET/CT was marginally more accurate than CT alone in N-
staging (p=0.04); no statistically significant difference was
found when compared to PET+CT for N-staging. PET/CT
altered further treatment in 13 patients compared to CT only
and in 7 patients compared to PET+CT.
Conclusion Combined PET/CT proved to be partly more
accurate in assessing the overall TNM-stage than CT and
PET+CT. These results were based on a higher accuracy
concerning the T-stage, mainly in patients with metallic
implants and marginally the N-stage. Therapy decisions
have been influenced in a substantial number of patients.
PET/CT might be considered as a first line diagnostic tool
in patients with suspected primary head and neck cancer.
Keywords Contrast-enhanced PET/CT. TNM staging .
Head and neck cancer . Therapeutic influence
Introduction
Head and neck cancer is one of the top ten leading cancers as
regard incidence [1]. Therapy of head and neck cancer patients
is complex, but multiple therapeutic regimens have been
developed over the past few years. Head and neck cancer
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therapy requires a multi-disciplinary approach including
oncology, surgery, radiotherapy and imaging service [2].
Initial staging is of particular importantce, since recurrent
and residual disease in head and neck cancer frequently do not
respond sufficiently to available therapy options [3–5].
Detection of head and neck tumours is performed clinically
with endoscopic procedures; however, tumour size, depth of
infiltration and the nodal status often evade characterisation.
Based on international staging guidelines morphology
imaging of the head and neck by means of CT and/or MRI
represents the method-of-choice for staging head and neck
cancer today [2, 6, 7]. Nevertheless, anatomical imaging
options are limited with respect to the detection of the tumour
sites and evaluation of the nodal disease [8–10]. Furthermore,
evaluation of morphological imaging can be challenging
based on the complex anatomy of the head and neck area. In
comparison, (18F)-fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (PET) has shown very good results
concerning tumour detection and detection of nodal metasta-
ses [8, 11, 12]. Sensitivities and specificities for FDG-PET in
head and neck cancer are as high as 87% and 94%, compared
to as low as 67% and 25% for CT and MRI, respectively [11,
12]. Recently, the combination of morphology and function
within a single, integrated PET/CT tomograph demonstrated
promising results concerning the detection and character-
isation of head and neck lesions. Furthermore, a potentially
positive impact on patient management has been indicated
[13–16]. However, most of the available head and neck
cancer studies today address the accuracy of PET/CT for
lesion detection rather than for complete TNM staging.
Furthermore, the majority of FDG-PET/CT scans included
in these studies are performed without CT contrast enhance-
ment, thus, rendering the CT images of poorer quality
compared to standard radiology examinations.
This study aims at assessing the diagnostic accuracy for
TNM staging in patients with suspected head and neck cancer.
First, the diagnostic accuracies for TNM stagingwith combined
PET/CT, CT-only and PET+CT (viewed side by side) were
compared. Second, we evaluated the lesion detection rates
(sensitivity, specificity, accuracy, NPV and PPV) for the
primary head and neck tumour sites, nodal metastases and
distant metastases for all four imaging modalities (CT-only,
PET-only, PET+CT side by side and combined PET/CT).
Finally, we assessed the impact of PET/CT on patient
management compared to the PET+CT and CT-only.
Patients and methods
Patients
The study was performed in accordance with the regulations
of the local institutional review board and ethics committee
for retrospective analysis. Informed consent was obtained
from all patients prior to the examination. Fifty-five patients
(mean age: 58 years; range: 34–94 years, 7 female, 48 male)
were included. All patients were referred for a combined
FDG-PET/CT examination based on the clinical suspicion of
a primary head and neck cancer. None of the patients suffered
from a known inflammatory disease in the head and neck area.
Local biopsy and histopathological workup was performed in
all patients after the FDG-PET/CT scan.
FDG-PET/CT imaging procedure
PET/CT imaging was conducted on a Biograph Duo PET/CT
system (Siemens Molecular Imaging, Hoffman Estates, IL).
The system is composed of a dual-slice CTscanner (Somatom
Emotion, Siemens Medical Solutions, Forchheim, Germany)
and a full-ring, BGO-based PET tomograph (Siemens
Molecular Imaging, Hoffman Estates, IL). The axial field-of-
view and in-plane, spatial resolution of the PET is 15.5 cm per
bed position and 4.6 mm, respectively. Glucose levels in all
patients were measured prior to the FDG injection. The
average administered FDG dose was 340MBq 60min prior to
the PET/CT examination. During the uptake time 1,500 ml of
a water-based, negative oral contrast agent was applied for
small bowel distension [17, 18].
A split imaging protocol was used for staging purposes.
For the first part of the scan patients were positioned supine
with their arms raised above the head.Following the CT
topogram (scout scan) a spiral CT scan was performed in the
caudo-cranial direction covering an axial imaging range from
the apex of the lungs to the mid-thighs. CT images were
acquired with 110 mAs, 120 kVp, 5-mm slice thickness, and a
2.4-mm incremental reconstruction. Contrast enhancement
was applied by means of 90 ml of an iodinated contrast agent
(300 mmol/ml, Guerbet GmbH, Sulzbach, Germany) with a
50-s delay in starting the CTand a flow rate of 3 ml/s. Patients
were instructed to hold their breath in normal expiration for
the duration of the CT scan of the lower thorax [19].
Subsequently, emission data were acquired for the same
co-axial field-of-view. The average PET acquisition time per
bed position was 3–5 min, depending on the weight of the
patient. PET images were corrected for scatter and attenua-
tion based on the available CT transmission images.
Following the torso scan patients were repositioned with
their arms down and the head and neck placed in a VacLock
bag for the second part of the scan [20]. Following the CT
topogram scan a spiral CT scan was performed covering
and axial imaging range from the upper skull to the apical
lobes of the lung. A start delay of 30 s was chosen for the
second contrast injection (70 ml of 300 mmol/ml, Guerbet
GmbH, Sulzbach, Germany, flow rate: 3 ml/s). CT images
in the head and neck area were acquired with 110 mAs,
120 kVp, 3-mm slice thickness and a 2.4-mm incremental
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reconstruction. Corresponding PET acquisition time was
3.5 min for each of the two bed positions covering the same
co-axial imaging range as the CT. Following CT-based
scatter and attenuation correction PET images were recon-
structed on 256×256 matrices, four iterations and eight
subsets to enhance visibility of smaller structures. Corrected
PET images were reconstructed iteratively (FORE-OSEM).
CT as well as PET data sets were viewed separately (CT,
PET, PET+CT) or in fused mode (PET/CT) on a commer-
cially available computer workstation (Siemens Molecular
Imaging, Erlangen, Germany). Thus, all compared imaging
modalities derived from the same data set.
Image evaluation
TNM staging
For this study, TNM staging was performed exclusively for
CT-only, PET+CT and PET/CT. The PET images were
evaluated with and without attenuation correction by two
nuclear medicine specialists in consensus. The CT images
were evaluated by two radiologists in consensus. Fused PET/
CT and PET+CT viewed side by side were evaluated by a
radiologist and a nuclear medicine specialist in consensus.
PET/CT and PET+CT readings were performed at least
2 months apart.
The participating readers were informed about the
patient-specific clinical background, but blinded to the
results of the other imaging procedures and the results of
the clinical investigation (e.g., endoscopy).
Lesion detection on combined PET/CT and PET+CT was
based on the detection of soft tissue masses with contrast
enhancement in conjunction with a focally increased glucose
metabolism above the surrounding tissue level. Furthermore, a
maximum standardised uptake value (SUVmax) of at least more
than 2.5 supported the diagnosis of a malignant lesion. The PET
threshold was adjusted to 40% of the maximum SUV, which
defines the size of the metabolically active lesion [21, 22].
The T stage was evaluated based on the tumour size and
surrounding tissue infiltration with corresponding elevated
glucose metabolism on PET/CT and PET+CT. Lymph
nodes were assessed for metastatic spread based on an
increased glucose metabolism and independent of their size
on PET/CT and PET+CT.
Distant metastases were assessed based on the detection
of soft tissue masses with contrast enhancement in different
body compartments and in conjunction with focally
increased glucose metabolism above the surrounding tissue
level. The diagnosis of a distant metastasis was furthermore
supported by an SUVmax of at least 2.5 (extrahepatic) and
3.5 (intrahepatic) [23]. In cases of malignant findings on
CT-only without focally increased glucose metabolism, the
lesions were evaluated based on CT criteria (see below).
On CT-only images, detection of soft tissue masses with
contrast enhancement characterised malignancy. The T stage
was assessed based on lesion size, surrounding tissue
infiltration, infiltration of other organs and the localisation
of the mass. The lymph node assessment was based on lesion
size: a threshold of 1.5 cm and 1.0 cm was used for jugulo-
digastric lymph nodes and all other lymph nodes of the neck,
respectively [24]. The overall TNM-stage for all tumour
types was assessed based on the current AJCC criteria for
all imaging procedures except PET imaging [25].
Lesion detection
Lesions detection was compared for all imaging modalities
(CT, PET, PET+CT and PET/CT) to show comparability
with the available literature and to demonstrate differences
of importance of lesion detection and TNM staging. CT,
PET+CT and PET/CT images were evaluated for lesion
detection based on the above mentioned criteria.
PET-only images were evaluated quantitatively and
qualitatively for areas of focally increased glucose metab-
olism above the surrounding tissue level, supported by a
SUVmax≥2.5 (excluding brain). However, PET-only
images were used to assess lesion detection rates, but not
TNM staging. This approach was chosen, because PET-
only imaging is not accepted as a primary imaging staging
procedure for head and neck cancer [2, 6, 7]. Volume and
size measurement of head and neck cancer based on PET-
only is a subject of great dispute, because T- and N-stage
evaluation can be impaired by the limited anatomical
resolution of the PET, thus rendering a surrounding tissue
infiltration, for example, challenging [26]. Hence, the PET
evaluation was restricted to lesion detection alone (sensi-
tivity, specificity, accuracy, NPV, PPV).
Change in management
The impact on patient management concerning the differ-
ences of the imaging results was assessed by the referring
physicians and the radiologists and nuclear medicine
specialists in consensus and was based on the international
clinical guidelines [6].
Standard of reference
In all patients histopathological evaluation and the resected
surgical specimen (tumours and/or lymph nodes) served as
the standard of reference for both T- and N-stage. Patients
who had a lymphoma only had biopsy. A mean follow-up
time of 407 days (range: 7–1,581 days) served as the
standard of reference for M0-staged patients. Short follow-
up times (<100 days) in two patients were due to benign
rather than malignant findings. Patients with M1 stage had
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histopathological confirmation of the suspected distant
metastases.
Statistical analysis
The primary endpoint of this study was the correct
classification of the overall TNM stage using CT and
PET+CT in comparison to PET/CT. Differences in TNM
staging between the different imaging procedures were
tested for significance using the exact McNemar’s test.
Bonferroni correction was applied to account for multiple
comparisons. The nominal significance level to evaluate the
two hypotheses of the primary analysis has to be 0.025 to
maintain a global significance level of 0.05. We calculated
95% confidence intervals (CI) according to Tango for the
difference in correlated proportions of the correct TNM
tumour stage [27].
Differences in the assessment of the T, N, and M-stages
between the imaging procedures (secondary endpoints)
were tested for significance using the exact McNemar’s
test with a significance level of 0.05.
Further endpoints included the determination of sensi-
tivities, specificities, negative predictive values (npv),
positive predictive values (ppv), and accuracies (with exact
95% confidence intervals) for tumour detection, for lymph
node detection, and distant metastases detection in all
modalities using histology as the standard of reference.
Statistical analyses were performed with SAS statistical
software (Version 9.1, SAS Institute Inc., Cary, NC).
Results
Patients
Fifty-five consecutive patients in a university hospital
setting underwent combined PET/CT imaging and were
included in this retrospective study.
The definitive diagnoses of tumour entities and/or benign
lesions were based on the standard of reference and are listed
in Table 1. The TNM-staging evaluation was based on 31
operated patients, respectively. Six patients with lymphoma
were excluded, as well as four patients with inflammatory
lesions (including one patient with lymph node tuberculo-
sis), and two patients with benign tumours. In 12 patients
no primary tumour was found (CUP: carcinoma of
unknown primary). In these patients, neck dissection based
on the PET/CT findings served as the standard of reference.
Overall accuracy of the different imaging procedures for
detection of malignant tumours was assessed based on 25
patients with primary tumour resection and additional neck
dissection; 6 patients had primary tumour resection only.
All patients tolerated the PET/CT procedure well.
TNM staging
Concerning the definition of the overall TNM-stage,
combined FDG-PET/CT imaging was significantly more
accurate (p<0.05; nominal significance level) than CT-only
(difference 55%; 95% CI: 38%–71%) and PET+CT
(difference 32%; 95% CI: 18%–50%) (p<0.05). The results
were based in parts PET/CT yielding a more accurate T-stage
(difference 65%; 95% CI: 46%–79%, p<0.05) (Fig. 1) and a
marginally more accurate N-stage (difference 29%; 95% CI:
4%–41%) (p=0.04) when compared to CT-only (Fig. 2).
However, compared to PET+CT the improvements in T-
staging from PET/CT were smaller (difference 32%; 95% CI:
18%–50%) (p<0.05); no significant difference was found for
N-stage (difference 13%; 95% CI: 0%–29%) (p>0.05)
(Fig. 3). Based on a patient-by-patient analysis, T-stage was
correctly determined in 27/31 patients (87%; CI: 70%–96%),
the N-stage in 24/31 patients (77%; CI: 59%–90%) and the M
stage in 30/31 patients (97%; CI: 83%–100%) with PET/CT.
The T-stage was correctly determined in 17/31 patients (55%;
CI: 36%–73%), the N-stage in 20/31 patients (65%; CI: 45%–
81%) and the M-stage in 30/31 patients (97%; CI: 83%–
100%) based on evaluation with PET+CT. The T-stage was
correctly determined in 7/31 patients (23%; CI: 10%–41%),
the N-stage in 17/31 patients (55%; CI: 36%–73%) and the
M-stage in 30/31 patients (97%; CI: 83%–100%) when
evaluated with CT-only. Consequently, combined PET/CT
imaging leads to fewer cases with under- or overestimated
TNM stages compared to the other imaging modalities. A
summary of all TNM staging results is shown in Table 2.
Table 1 Definitive diagnosis after surgery and/or neck dissection and
biopsy
Definitive diagnoses (tumour entities and benign lesions) Patients
Carcinoma of the oral cavitiy 9
Carcinoma of the nasopharynx 1
Carcinoma of the oropharynx 5
Carcinoma of the hypopharynx 3
Esophagus carcinoma 1
Carcinoma of the larynx
-Supraglottic 7
-Glottic 4
Carcinoma of the outer ear 1
Carcinoma of unknown primary 12
Hodgkin’s disease 2
Non-Hodgkin’s lymphoma 4
Inflammatory lesions 3
Lymph node tuberculosis 1
Nasopharyngeal cyst 1
Choanal/pharyngeal polyp 1
Total 55
Six patients only received biopsy and did not undergo additional
surgery based on histopathological findings (lymphoma).
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Patients with CUP and benign lesions
No primary tumour was found in 12 patients with suspected
head and neck cancer. Consequently, these patients were
classified as CUP patients. When evaluating the N-stage
and M-stage in these 12 CUP patients, 1 patient was
overstaged, 1 patient was understaged and 10 patients were
correctly staged with PET/CT, whereas 2 patients were over-
staged, 1 patient was understaged and 9 patients were cor-
rectly staged with PET+CT compared to the standard of
reference. When staged with CT-only, one patient was
overstaged, four patients were understaged and seven
patients were staged correctly, respectively.
Furthermore, several benign or non-malignant lesions
were detected (one osteomyelitis at the base of the skull,
one tonsilitis, one clotted internal jugular vein with
surrounding inflammation, one lymph node tuberculosis,
one cyst and one choanal/pharyngeal polyp). All modalities
(CT-only, PET+CT and PET/CT) were evaluated false
positive in one patient with lymph node tuberculosis. In
one case with osteomyelitis at the base of the skull the
dorsal nasopharyngeal wall was thickened and showed a
high consecutive FDG uptake. These findings were falsely
interpreted as tumour by all readers in all modalities.
Lesion detection
Combined FDG-PET/CT showed a higher detection rate
(97%; CI: 83%–100%) than PET+CT (90%; CI: 74%–98%/
p>0.05), CT-only (58%; CI: 39%–75%, p<0.05) and PET-
only (87%; CI: 70%–96%, p>0.05) for the detection of the
primary tumour. Hence, a statistical significant difference
was detected only when compared to CT-only. However,
assessing lymph node detection, PET/CT and PET+CT
Fig. 1 A 56-year-old male patient with suspected epipharyngeal
cancer. (a) Axial CT image shows symmetric pharyngeal structures in
a patient with suspected epipharyngeal cancer. Furthermore, no
suspicious contrast enhancement or thickening of the dorsal epipha-
ryngeal wall (white arrow) or other pharyngeal wall structures were
detected. Thus, on CT images, the tumour was overlooked by the
reader team. (b) Corresponding axial PET image of the same area
shows a focally increased glucose metabolism at the right epipha-
ryngeal wall. On PET images alone, exact localisation of the increased
glucose metabolism is challenging. However, on PET images, the
tumour was detected (true-positive result). (c) Corresponding axial
PET/CT image shows an area of increased glucose metabolism in the
non-thickened right epipharyngeal wall. Furthermore, there is an
asymmetric distribution of tracer activity compared to the left tonsil.
Thus, on PET/CT images, the tumour was correctly detected, localised
and characterised. The T-stage was confirmed by subsequent surgical
resection and histopathological workup
Fig. 2 An 83-year-old female patient with suspected oropharyngeal
cancer. (a) Axial PET image shows an area of increased glucose
metabolism right cervically/retroclavicularly. However, no other area
with a pathologically increased glucose metabolism could be detected
in any pharyngeal section (not shown). (b) Axial CT of the same
patient shows a 5-mm lesion (white arrow). On CT alone this small
lymph node was considered not malignant. On side-by-side viewing,
the lymph node was detected and evaluated as suspicious for
metastatic spread. (c) Fused PET/CT detected elevated glucose
metabolism within this small lymph node. Consecutive resection
confirmed metastatic spread in this lymph node. However, also on
PET/CT no primary tumour could be detected in any pharyngeal
section. Thus, in this patient the diagnosis remained CUP
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yield similar diagnostic accuracies and no statistically
significant difference was found to PET-only and CT-only.
Table 3 summarizes the overall detection rates for the
primary tumour and lymph node metastases.
Therapy alteration
The impact on patient therapy was assessed based on
international clinical guidelines [6]. In seven patients, there
was additional information provided by combined PET/CT
not afforded by PET+CT side by side, which altered the
therapeutical management (7/31 patients, 23%). Compared
to PET+CT, PET/CT-based therapy changes derived from
upstaging in six patients with consecutive alteration of the
surgical extent. This was based on six patients with more
accurate T-stage evaluation, and no therapy alteration was
achieved by more accurate lymph node evaluation. PET/CT
allowed for correct downstaging in one patient, thus,
preventing the patient from unnecessary surgery. Staging
based on combined PET/CT imaging altered the therapy in
13/31 patients (42%) compared to CT-only. In eight of these
patients the T-stage was characterised more accurately with
PET/CT, thus resulting in an increase of the surgical extent.
In one patient, FDG-PET/CT was able to upstage both T-
stage and N-stage, leading to more extensive surgery. Correct
downstaging was possible in four patients when comparing
PET/CT to CT-only readings, thus, reducing the extent of the
surgery for the primary tumour. Since there was only a
marginally significantly more accurate lymph node evalua-
tion (p=0.04) with PET/CT vs. CT-only, no change in
therapy was found concerning the N-stage evaluation.
Discussion
Whole-body PET/CT with a dedicated, contrast-enhanced
head and neck protocol proved to be partly significantly
superior in overall TNM staging of suspected primary head
and neck cancers compared to PET+CT and compared to
contrast-enhanced CT-only. These results were mainly
based on a significantly more accurate T-staging (p<0.05)
compared to PET+CT and CT-only based on better
visibility in patients with metallic oral implants. Only a
barely more accurate N-staging (p=0.04) compared to CT-
only was found. However, PET/CT changed the therapy in
a substantial number of patients compared to the compared
Table 2 TNM staging results
Correctly staged
patients/95%-CI
Overstaged
patients
Understaged
patients
TNM stage
PET/CT 34/49/55%–82% 6/49 9/49
PET+CT 23/49/33%–62% 7/49 19/49
CT 15/49/18%–45% 7/49 27/49
T stage
PET/CT 44/49/78%–97% 2/49 3/49
PET+CT 32/49/50%–78% 4/49 13/49
CT 24/49/34%–64% 5/49 20/49
N stage
PET/CT 38/49/63%–88% 5/49 6/49
PET+CT 34/49/55%–82% 8/49 7/49
CT 30/49/46%–75% 7/49 12/49
M stage
PET/CT 48/49/89%–100% 1/49 0/49
PET+CT 47/49/86%–100% 2/49 0/49
CT 48/49/89%–100% 0/49 1/49
Staging results with the different imaging modalities for the overall
TNM-stage, for the T-stage, the N-stage, and the M-stage including
overstaging and understaging
Forty-nine represents the total number of patients including benign
lesions and CUP patients. Six patients of the total study population
had to be excluded from TNM-staging as they were found to have
lymphoma (95% CI)
Fig. 3 A 67-year-old female patient with suspected supraglottic,
laryngeal cancer. (a) The axial CT image shows a nodular, thickened
pharyngeal/laryngeal wall (bold white arrows). A small lymph node
left cervically was overlooked based on its size and proximity to the
M. sternocleidomastoideus (thin white arrow). (b) The axial PET
image shows an elevated glucose metabolism of the pharyngeal/
laryngeal wall. Furthermore, a small area with elevated glucose
metabolism was detected left cervically. Thus, on side-by-side imaging
the tumour as well as the lymph node metastasis were detected. (c)
Combined PET/CT shows the tumour with elevated glucose metab-
olism right cervically as well as the small lymph node with elevated
glucose metabolism left cervically. PET/CT was correct in tumour
detection and lymph node detection. Hence, PET/CT was superior in
lymph node detection over CT alone, but not over PET+CT
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imaging modalities. Thus, our study suggests that staging,
rather than lesion detection only, is important for therapy
influence. Overall, PET/CT therefore may be considered as
the first line diagnostic option in staging patients with
suspected primary head and neck cancer.
Lesion detection
Lesions detection was compared for all lesions and all
imaging modalities (CT, PET, PET+CT and PET/CT) to
show comparability with the available literature and to
demonstrate differences of importance of lesions detection
and TNM-staging.
PET/CT vs. PET
Although cross-sectional imaging has been recommended
as the first-line tool for tumour detection in the head and
neck area, PET has already shown outstanding results
concerning staging of head and neck cancers with focus on
tumour detection and lymph node assessment [9, 11, 28,
29]. Our results concerning lymph node detection and
detection of the primary tumour are well in accordance with
the current literature. When comparing overall lesion
detection (primary tumour and metastatic lymph nodes) of
PET and PET/CT, comparable studies indicated sensitivities
of 67%–93% and up to 100% for the specificity with PET,
respectively [8, 12, 30]. For PET/CT, sensitivities of up to
100% and specificities ranging from 77%–92% have been
reported [13, 14, 31]. In the head and neck area, the
complex anatomy and the varying physiological uptake of
FDG renders PET-only interpretation difficult and chal-
lenging [15, 32, 33]. The availability of complementary CT-
data in PET/CT may help to overcome those interpretation
difficulties.
PET/CT vs. CT
For detection of malignancy with CT, we found a relatively
low sensitivity, but high specificity for primary tumour
detection and reasonable results for lymph node detection.
Lesion detection rates have been discussed controversially
for CT with reported sensitivities and specificities ranging
from 25%–74% and 25%–75% for the primary lesion and
up to 97% sensitivities and specificities for lymph node
detection, respectively [13, 30, 34, 35]. One reason for the
differences may be that most of the other studies included
an inhomogeneous patient population evaluating primary
and recurrent cancers, while we concentrated on primary
cancers in patients who had not received previous treat-
ment. Additionally, CT staging can be heavily impacted by
metallic implants, as this was present in a significant
number of patients in our population. In those cases,
additional functional information can be of substantial help.
Overall, CT staging in this particular clinical setting was not
as reliable, especially in T-staging, as combined imaging.
Table 3 Lesion detection
Sensitivity/95%-
CI
n Specificity/95%-
CI
n Accuracy/95%-
CI
n PPV/95% CI n NPV/95% CI n
A. Tumour detection
PET/CT 97%/83%–100% 31 94%/73%–100% 18 96%/86%–100% 49 97%/83%–100% 31 94%/73%–100% 18
PET+CT 90%/74%–98% 31 83%/59%–96% 18 88%/75%–95% 49 90%/74%–98% 31 83%/59%–96% 18
CT 58%/39%–75% 31 94%/73%–100% 18 71%/57%–83% 49 95%/74%–100% 19 57%/37%–75% 30
PET 87%/70%–96% 31 83%/59%–96% 18 86%/73%–94% 49 90%/73%–98% 30 79%/54%–94% 19
B. Lymph node detection
PET/CT 87%/70%–96% 31 79%/58%–93% 24 84%/71%–92% 55 84%/67%–95% 32 83%/61%–95% 23
PET+CT 87%/70%–96% 31 67%/45%–84% 24 78%/65%–88% 55 77%/60%–90% 35 80%/56%–94% 20
CT 77%/59%–90% 31 75%/53%–90% 24 76%/63%–87% 55 80%/61%–92% 30 27%/51%–88% 25
PET 81%/63%–93% 31 71%/49%–87% 24 76%/63%–87% 55 78%/60%–91% 32 74%/52%–90% 23
C. Distant metastases detection
PET/CT 100%/29%–100% 3 98%/88%–100% 46 98%/89%–100% 49 75%/19%–99% 4 100%/92%–
100%
45
PET+CT 100%/29%–100% 3 96%/85%–99% 46 96%/86%–100% 49 60%/15%–95% 5 100%/92%–
100%
44
CT 67/9%–100% 3 100%/92%–100% 46 98%/89%–100% 49 100%/16%–
100%
2 98%/89%–100% 47
PET 33%/1%–91% 3 93%/82%–99% 46 90%/78%–97% 49 25%/1%–81% 4 96%/85%–99% 45
Rates for primary tumour detection (Table 4A), lymph node detection (Table 4B), and detection of distant metastases (Table 4C). Patients with
cervical lymphoma have been included for evaluation of lymph node detection (n=55)
PPV: positive predictive value, NPV: negative predictive value, CI: confidence interval; n= number of patients evaluation is based on
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PET/CT vs. PET+CT
We noticed only minor differences when comparing PET/
CT and PET+CT for lymph node detection and M-staging.
Therefore, PET+CT might be generally considered a suf-
ficient alternative. Several issues have to be kept in mind
when comparing two dedicated procedures with an inte-
grated PET/CT: despite the logistical and time-consuming
disadvantages for the patient, the referring physician has to
combine two reports on his/her own. Being a clinical
physician, this might be time consuming and sometimes
challenging, too. Furthermore, those similar results might be
overestimated for several reasons (see limitations).
TNM-staging and therapy alterations
Only a few studies have been published concerning
combined imaging with PET/CT in head and neck cancer
and mainly lesion detection and positive effects of PET/CT
on localisation over CT alone and PET alone were
evaluated rather than TNM-staging. In one study, Schoeder
and co-workers defined the accuracy of PET/CT in N0-
staged cervical lymph nodes defined by clinical examina-
tion, CT and MRI. Compared to our results, a lower
sensitivity, but a higher specificity and a comparable
accuracy were found [16]. In this study, the surgical plan
was not influenced by the PET/CT- findings, because risk
stratification was already based on the conventional
workup. The difference in our study is that the PET/CT in
our centre was already accepted as the standard of care by
the operating physician because it contained a contrast-
enhanced CT. Therefore, we found a higher diagnostic impact.
In another study, Schoeder et al. evaluated the reader
confidence defined by a qualitative score. They found a
higher diagnostic confidence with consecutive affected
patient care based on the PET/CT findings, but therapeutic
treatment was altered in 4 of 68 patients when compared to
PET-only [29]. Thus, the effect on patient care was mainly
due to additional imaging studies, which could be avoided
by the higher diagnostic confidence. In a recent study by
Connell et al. the TNM classification was altered by PET/
CT when compared to the conventional clinical workup in
34%, representing a similar range compared to our findings
[36]. Moreover, the radiotherapy was influenced in 29% of
the patients based on PET/CT findings. Again, our results,
even retrospectively evaluated, are showing the same range
of influence on therapy management. However, in discrep-
ancy to our study, histopathological verification of the
malignant findings were not commonly optained.
Branstetter et al. evaluated the improvement of reader
confidence concerning the lesion detection and character-
isation, too. They found an improvement in 62% of lesions
compared to CTalone and in 41% of lesions compared to PET
alone [13]. Our results point out a similar trend. Overall, the
combination of increased reader confidence (i.e., more
lesions were detected and characterised as malignant than
in CT-only) and the additional information afforded by the
PET-component mainly contributed to the therapeutical
influence of the PET/CT findings in our study.
In our study, PET/CTcorrectly changed consecutive therapy
in a substantial number of patients compared to CT alone and
compared to PET+CT. Alterations of patient management
mainly derived from a more accurate overall TNM-staging and
mainly upstaging. Therapy alterations, as evaluated in this
study, were based on standard clinical guidelines, but were
conducted retrospectively. These therapy alterations must
therefore be considered “potential” therapy alterations, be-
cause, in prospective evaluations, individual decisions of the
patient and/or the physician can lead to different therapies.
However, these retrospective evaluations still represent clinical
routine, at least to a certain extent. Although we could
demonstrate an advantage in TNM-staging and showed
therapy changes based on PET/CT compared to the other
modalities, it still needs to be proven if these therapeutic
influences have an effect on survival or quality of live.
Limitations
Limiting factors: PET/CT imaging
There are some limitations to the PET/CT procedure:
Metallic implant artefacts not only can cause difficulties
in CT reading, but also in PET/CT due to artefacts caused
by the CT-based PET attenuation correction. However, in
those cases, evaluation of the non-corrected PET images are
of additional help. Therefore, PET/CT can overcome
classical CT-based evaluation difficulties, especially in
patients with disturbing metallic oral implants.
CT-only imaging in this study arose from the combined
PET/CTacquisition. Thus, resolutionwas limited based on the
technical capabilities of the used dual-slice scanner. In reality,
state-of-the-art multi-slice CT scanners meanwhile can pro-
vide much higher resolution with only slightly increased
noise, providing (together with a dedicated contrast media
protocol) a significantly higher reader confidence. Further-
more, a dedicated head and neck CT is generally conducted
with an angled (parallel to the base of the skull) acquisition
projection and a different contrast media protocol. Due to
geometrical limitations of the PET/CT, tilting of the gantry is
not feasible for PET/CT. These non-angled CT images may
have an impact on the detection of small lesions, especially at
the base of the skull.
Based on a varying glucose uptake in the head and neck
area, detection and staging of malignant lesions can be
challenging [33, 37]. Especially the tonsils, as well as the
vocal cords, may show a high SUV, leading to false-positive
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findings [32, 33]. Inflammation is another major pitfall in
evaluation of ENT cancer. In our patient population, two
patients were evaluated false positive based on inflammatory
lesions, too. Different approaches to differentiate between
inflammation and tumour with dual-time PET or alternative
tracers have shown promising results, but have not been
implemented in clinical routine [8, 38].
Limiting factors: study design
The study design itself has some limitations. Only a small
number of patients are included in our study at first sight.
However, it has to be noted that only patient with primary
suspicion of head and neck cancer and with a complete
histopathological workup were included in our study. Certain-
ly, significantly more patients with head and neck malignan-
cies are examined in our institution, but a significant number of
patients are treated with radiotherapy and/or chemotherapy
rather than primary surgery. In these patients, only a mixed
standard of reference (histopathology, clinical course, labora-
tory reports, imaging follow-up) was available. As one aim of
the study was to compare the imaging modalities concerning
TNM-staging with the most adequate standard of reference
(histopathology), primary tumour operation and/or neck
dissection conducted before any additional therapy was
needed. Thus, a large number of patients had to be excluded.
However, false-negative lymph nodes could partly only be
evaluated based on clinical follow-up, because neck dissection
was not always performed in patients where no cervical lymph
node metastases were suspected.
In clinical routine, pre-therapeutic staging is not only
based on imaging findings, but also on endoscopical
procedures. The combination of endoscopical procedures
with PET/CT imaging will probably serve as the most
sophisticated approach for staging of head and neck tumours.
Small, but important findings on endoscopy (e.g., fixation of
the vocal cord) have additional impact on T-staging. PET/CT
then may provide complementary N-staging and M-staging
for further therapy planning.
Patients with CUP (carcinoma of unknown primary)
were also evaluated in our study. It has been reported in the
literature that in some patients with CUP, no primary
tumour will be detected during the course of the disease
with any diagnostic method [16, 39]. In our study, the
primary tumour was not found during the clinical follow-up
in those patients as well; thus, they had been excluded from
the overall TNM evaluation as well.
Finally, minor differences were detected when compar-
ing tumour staging with PET/CT and PET+CT. In clinical
routine, CT and PET for side-by-side evaluation used to be
acquired on different scanners, leading to different patient
positioning on the examination tables, different organ
positions based on respiration and organ shift and based
on different fields of view. We tried to mimic those
situations by manual misalignment of CT and PET on two
different screens. This might be the reason why PET/CT
performed significantly better in T-staging evaluation than
PET+CT. Therefore, in clinical routine, side-by-side image
evaluation, when acquired separately on different scanners,
remains challenging and will probably be less accurate than
combined PET/CT. Additionally, the vast majority of
scanners that are actually sold are PET/CT-scanners, rather
than PET-only scanners.
Conclusion
Contrast-enhanced FDG-PET/CT was partly superior in
TNM-staging of head and neck cancer compared to
contrast-enhanced CT-only and PET+CT. This was based
on a more reliable T-staging, partly due to better primary
tumour delineation on co-registered PET/CT in patients with
metallic artefacts. PET/CT could lead to a change in patient
management in a substantial number of patients when
compared to CT-only and PET+CT. PET/CT, PET+CT and
PET-only performed equally well for lesion detection. In
summary, contrast-enhanced, combined FDG-PET/CT im-
aging might be considered appropriate to replace single CT-
and PET imaging for staging head and neck tumours.
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